Kedrion and ProMetic Form Strategic Alliance to Develop Orphan Drugs from Plasma
Advertisement
Kedrion S.p.A. and ProMetic BioTherapeutics, Inc., a subsidiary of ProMetic Life Sciences Inc. have formed a strategic alliance to develop orphan drugs derived from human plasma utilizing ProMetic's proprietary manufacturing process, the Plasma protein purification System (PPPS).
The alliance between the two companies was created to select specific proteins which can be manufactured into drugs that either have received orphan drug designation or have the potential to receive it. High value plasma proteins have long served as therapeutics for a wide variety of disorders including many rare diseases. The PPPS technology, which was co-developed with The American Red Cross, can be applied to the recovery of certain proteins that have established therapeutic value but cannot be extracted effectively via current manufacturing practices, or that are not the focus of large plasma fractionators.
Although the financial details of the alliance were not disclosed, ProMetic and Kedrion will share in the revenue derived from the sales of commercialized therapeutics and will initially target Europe.
PPPS is an application of ProMetic's core technology to extract the most valuable therapeutic proteins from plasma. Each protein is removed from plasma by a specific ProMetic Mimetic Ligand(TM) adsorbent and subsequently purified in a side stream. According to the company, the removal sequence has been optimized to give exceptionally high protein recoveries at unprecedented activity levels. One of the latent and most promising aspects of PPPS technology is its ability to recover additional new proteins that could treat uncommon diseases and thus benefit from orphan drug status.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patent
QIAGEN and ActiveSight Sign Co-Marketing Agreement Targeting Protein Crystallography
U.S. Development Partner Quest Diagnostics Completes Clinical Development of Septin9 Colorectal Cancer Blood Test
Global Pharmaceutical companies expect hard price competition in the rising Biosimilars segment - Bi-annual survey among more than 80 executives from globally active pharmaceutical companies based in 16 countries and spread over four continents
Metobolomics uncovers key indicators of nonalcoholic fatty liver disease - Impaired oxidation in liver associated with progression to NASH
Converting carbon dioxide into useful chemicals with the help of bacteria and solar power - How electrolysis and fermentation can be combined in one system
Agilent Technologies Presents Thought Leader Award to Lipidomics Expert Dr. Jules Griffin - Cambridge Researcher to Further Studies of Obesity, Fatty Liver Disease
3D images display plant organs down to the smallest detail - Intelligent software for a better understanding of plant tissue development
Antibiotic treatment increases the severity of asthma in young mice
Children with rare, incurable brain disease improve after gene therapy
